Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lisymt Europa
Munich, Bavaria, Germanylisymt.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lisymt is a biotechnology company focused on developing innovative small molecule therapeutics for lysosomal storage disorders and neurodegenerative diseases. The company's primary research centers on the modulation of the glucosylceramidase (GBA) enzyme, which is a critical factor in the pathogenesis of Gaucher disease and GBA-associated Parkinson's disease. By leveraging deep expertise in lysosomal biology, Lisymt aims to restore cellular homeostasis and provide disease-modifying treatments for patients with high unmet medical needs. The company is currently advancing its lead programs through the pre-clinical stage of development.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Lisymt Europa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lisymt Europa.